Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael A Bookman

Showing results (1-10 of 102) with videos related to

Pageof 11
Sort By:
Lancet (London, England)|September 22, 2009
Dose-dense chemotherapy in advanced ovarian cancerMichael A Bookman
Journal of Gynecologic Oncology|May 9, 2013
Should studies of maintenance therapy be maintained in women with ovarian cancer?Michael A Bookman
Cancer|January 23, 2020
Can we predict who lives long with ovarian cancer?Michael A Bookman
Journal of the National Cancer Institute|November 23, 2013
Molecular wanderings through the DNA damage response and risk for ovarian cancerMichael A Bookman
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|December 4, 2009
Trials with impact on clinical management: first lineMichael A Bookman
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 13, 2017
In Accordance With Our Best EstimatesMichael A Bookman
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 20, 2011
Update of randomized trials in first-line treatmentMichael A Bookman
Clinical Obstetrics and Gynecology|February 21, 2012
First-line chemotherapy in epithelial ovarian cancerMichael A Bookman
Seminars in Oncology|February 13, 2002
Developmental chemotherapy in advanced ovarian cancer: incorporation of newer cytotoxic agents in a phase III randomized trial of the Gynecologic Oncology Group (GOG-0182)Michael A Bookman
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 20, 2007
Developmental chemotherapy and management of recurrent ovarian cancerMichael A Bookman
Pageof 11

Showing results (1-10 of 102) with videos related to

Sort By:
Pageof 11
Lancet (London, England)|September 22, 2009
Dose-dense chemotherapy in advanced ovarian cancerMichael A Bookman
Journal of Gynecologic Oncology|May 9, 2013
Should studies of maintenance therapy be maintained in women with ovarian cancer?Michael A Bookman
Cancer|January 23, 2020
Can we predict who lives long with ovarian cancer?Michael A Bookman
Journal of the National Cancer Institute|November 23, 2013
Molecular wanderings through the DNA damage response and risk for ovarian cancerMichael A Bookman
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|December 4, 2009
Trials with impact on clinical management: first lineMichael A Bookman
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 13, 2017
In Accordance With Our Best EstimatesMichael A Bookman
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 20, 2011
Update of randomized trials in first-line treatmentMichael A Bookman
Clinical Obstetrics and Gynecology|February 21, 2012
First-line chemotherapy in epithelial ovarian cancerMichael A Bookman
Seminars in Oncology|February 13, 2002
Developmental chemotherapy in advanced ovarian cancer: incorporation of newer cytotoxic agents in a phase III randomized trial of the Gynecologic Oncology Group (GOG-0182)Michael A Bookman
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 20, 2007
Developmental chemotherapy and management of recurrent ovarian cancerMichael A Bookman
Pageof 11